A detailed history of Lindbrook Capital, LLC transactions in Evolus, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 21 shares of EOLS stock, worth $254. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21
Holding current value
$254
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$10.66 - $17.48 $223 - $367
21 New
21 $0
Q2 2023

Jul 28, 2023

BUY
$7.23 - $10.52 $28 - $42
4 New
4 $0
Q3 2022

Nov 10, 2022

SELL
$7.76 - $13.72 $985 - $1,742
-127 Reduced 63.5%
73 $1,000
Q1 2022

Apr 21, 2022

BUY
$5.22 - $11.78 $1,044 - $2,356
200 New
200 $2,000
Q3 2021

Nov 05, 2021

SELL
$7.36 - $13.67 $2,156 - $4,005
-293 Closed
0 $0
Q2 2021

Jul 27, 2021

BUY
$8.42 - $13.96 $2,467 - $4,090
293 New
293 $4,000

Others Institutions Holding EOLS

About Evolus, Inc.


  • Ticker EOLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 56,094,800
  • Market Cap $680M
  • Description
  • Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...
More about EOLS
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.